Form 8-K

8-K — Vivani Medical, Inc.

Accession: 0001753926-26-001482

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001266806

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — vani-20260813.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ex991_1.htm)

EX-99.2 — EXHIBIT 99.2 (ex992_2.htm)

GRAPHIC (c58226787c358962998b.jpg)

GRAPHIC (c00b47d69f7899bdc6cd.jpg)

GRAPHIC (c058689b744bff831336.jpg)

GRAPHIC (c0daa804ee3ab3ce286e.jpg)

GRAPHIC (c0ea1236879c02986db0.jpg)

GRAPHIC (c2bacfce5a1fc6631160.jpg)

GRAPHIC (c2cc11d818ac7c73e556.jpg)

GRAPHIC (c322c3e2ca6be4462801.jpg)

GRAPHIC (c35284f84549fb617044.jpg)

GRAPHIC (c3afdc1f3293f6ef3869.jpg)

GRAPHIC (c3f0a831d3bfb96e1672.jpg)

GRAPHIC (c46104a4dd2e05b801c2.jpg)

GRAPHIC (c5ba78f1a1c037430954.jpg)

GRAPHIC (c5c84745a5a6c3a581fe.jpg)

GRAPHIC (c73e7a41737f01dd32fb.jpg)

GRAPHIC (c8c360b9a488cb7d461e.jpg)

GRAPHIC (c92a6992ae5b36a6f53c.jpg)

GRAPHIC (c96a813c046e1038d184.jpg)

GRAPHIC (c9fad373b5b2c1237908.jpg)

GRAPHIC (ca29c376ff5dd7b81ee4.jpg)

GRAPHIC (cb4d791da4caf7a769c3.jpg)

GRAPHIC (cc19df2b4bd7d8be9d8f.jpg)

GRAPHIC (cc5bd2d34a29c3bcf6ed.jpg)

GRAPHIC (cc7ca4cd63c5bb898143.jpg)

GRAPHIC (ccd8ba484161695f463a.jpg)

GRAPHIC (cdf4ab4bf811d5a9e134.jpg)

GRAPHIC (cdfe3f12a008796488ef.jpg)

GRAPHIC (ce8a8c0df93dc5d40fdb.jpg)

GRAPHIC (cf653aa88cccf445f363.jpg)

GRAPHIC (cfd8c142b5ceb10e6134.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: vani-20260813.htm · Sequence: 1

vani-20260813.htm

false

000126680600012668062026-08-132026-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2026

Vivani Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36747

02-0692322

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1350 S. Loop Road

Alameda, California

(Address of principal executive offices)

94502

(Zip Code)

Registrant’s telephone number, including area code: (415) 506-8462

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

VANI

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2026, Vivani Medical, Inc. (the “Company”) issued a press release entitled “Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update” which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

Item 7.01. Regulation FD Disclosure

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. These slides are attached to this Current Report on Form 8-K as Exhibit 99.2 and are incorporated by reference herein. The Company is also posting to the “Investors” portion of its website a copy of its current corporate slide presentation. The slides speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the slides in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

The information contained in this Item 7.01 and Exhibit 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release issued August 13, 2026.

99.2

Vivani Medical, Inc. slide presentation dated August 13, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIVANI MEDICAL, INC.

Date: August 13, 2026

By:

/s/ Donald Dwyer

Name:

Donald Dwyer

Title:

Chief Business Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex991_1.htm · Sequence: 7

Exhibit 99.1

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026

Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology

Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT anticipated in the third quarter of 2026

ALAMEDA, Calif., August 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress.

"I am very pleased with the progress and achievements that Vivani made in all aspects of our business during the second quarter of 2026. We accelerated clinical development of lead asset NPM-139 (semaglutide implant), entered into a non-exclusive agreement with Novo Nordisk enabling them to evaluate NPM-139, and signed a merger agreement with Nasdaq-listed ClearOne which, upon successful closing, would finance and establish our neurostimulation subsidiary Cortigent as a stand-alone publicly traded company," said Adam Mendelsohn, Ph.D., CEO of Vivani Medical. "We enrolled and dosed all 20 SLIM-1 participants ahead of schedule, with every insertion procedure completed successfully. We expect to be able to share top-line data in November, an exciting milestone that we anticipate will support advancing NPM-139 into a Phase 2 dose-ranging trial in 2027. Combined with the agreement with Novo Nordisk announced in July, these positive developments further strengthen our conviction in the potential of our pipeline to transform chronic disease management for the roughly half of patients who struggle with medication adherence. Today, Vivani remains the only developer of convenient, ultra-long-acting and reversible GLP-1 candidates with the potential for administration once- or twice yearly during a routine primary care office visit."

Vivani’s NanoPortal implant technology has the potential to enable patients to maintain continuous and therapeutic drug exposure levels with convenient once or twice-yearly administration while still enabling the ability to rapidly reverse GLP-1 drug exposure in patients when cessation of therapy is needed or desired. Reversibility can be an important clinical consideration in certain situations including when a woman becomes pregnant or when patients undergoing surgery have an increased aspiration risk.

Recent Business Highlights

On August 6, 2026, Vivani announced full enrollment and successful initial dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant designed to provide six- to twelve-months of continuous drug delivery utilizing its proprietary NanoPortal™ technology. The trial of 20 GLP-1 naïve participants in Australia includes low-doses of NPM-139 and Wegovy® to assess safety, tolerability, and pharmacokinetics. Changes in weight will be measured. Top-line data from SLIM-1 are expected in November 2026, which the Company anticipates will pave the way for initiation of a Phase 2 dose-ranging trial in 2027.

On July 7, 2026, the Company announced the signing of an agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary NanoPortal technology associated with this agreement.

Also in July 2026, Vivani announced that its wholly owned subsidiary Cortigent, Inc., a developer of brain-computer interface devices based on precision neurostimulation technology, entered into a definitive merger agreement with Nasdaq-listed ClearOne, Inc. The transaction, which is expected to close in the third quarter of 2026 subject to customary closing conditions, is designed to establish Cortigent as a separately listed public company, reduce Vivani's direct expenditures related to Cortigent, and enable the Vivani team to focus fully on advancing its portfolio of miniature, ultra long-acting drug implants.

On June 26, 2026, the Company announced the appointment of August J. Moretti to its board of directors. Mr. Moretti joins the board with extensive operating and financial executive experience spanning all phases of company growth. Mr. Moretti served as CFO of 4D Molecular Therapeutics from 2019 until his retirement. Prior to this he held CFO positions at Assertio Therapeutics until its acquisition by Zydus Lifesciences; Alexza Pharmaceuticals until its acquisition by Ferrer Pharmaceuticals; and Alavita, Inc. Mr. Moretti holds a B.A. in Economics from Princeton University and a J.D. from Harvard Law School.

On June 25, 2026, Vivani announced that it had received approval from Bellberry, a human research ethics committee (HREC) in Australia to initiate SLIM-1™, a Phase 1 clinical trial of NPM-139, a semaglutide implant.

Upcoming Anticipated Milestones

Completion of SLIM-1, the on-going Phase 1 study of low-dose NPM-139, Vivani’s miniature, ultra long-acting semaglutide implant under development for chronic weight management, and anticipated reporting of top-line results in November 2026.

Preparation, and submission of an Investigational New Drug (“IND”) Application for NPM-139 to support initiation of a proposed Phase 2 dose-ranging study of this semaglutide implant planned for 2027.

Transition of Cortigent into an independent, publicly traded company following completion of all customary closing and related financing activities. We anticipate establishment of the post-merger company, renamed Cortigent Holdings (d/b/a Cortigent), to be traded on the Nasdaq exchange under the ticker CRGT in the third quarter of 2026.

Second Quarter 2026 Financial Results

Cash: As of June 30, 2026, Vivani had cash, cash equivalents and restricted cash totaling $20.8 million, compared to $17.6 million as of December 31, 2025. The increase of $3.2 million is primarily attributed to tranche closings associated with share purchase agreements entered into in 2025 with an entity affiliated with one of our independent directors and a private placement and registered direct offering completed in January, 2026, offset by net loss for the six months ending June 30, 2026, of $13.2 million.

Research and development expense, net of grants: Research and development expense, net of grants, during the three months ended June 30, 2026 was $4.5 million, compared to $4.8 million during the three months ended June 30, 2025. The decrease of $0.3 million, or 6%, was primarily attributable to the decrease in both the clinical trial related expense and development expense from our Biopharm Division.

General and administrative expense, net of grants: General and administrative expense, net of grants, during the three months ended June 30, 2026 was $2.4 million, compared to $2.7 million during the three months ended June 30, 2025. The decrease of $0.3 million, or 11%, was primarily attributable to the decrease in the professional services from our Neurostimulation Division and our Biopharm Division.

Other income, net: Other income, net during the three months ended June 30, 2026 was $0.5 million, compared to $0.3 million during the three months ended June 30, 2025. The increase of $0.2 million was primarily attributable to the derecognition of a contract liability previously held by the Neurostimulation Division, offset by lower interest income earned during the period

Net loss: For the foregoing reasons, we had a net loss of $6.4 million during the three months ended June 30, 2026 compared to $7.1 million during the three months ended June 30, 2025.

About SLIM-1™ Trial

SLIM-1 is an open-label, active-controlled trial evaluating a low-dose NPM-139 (semaglutide implant) given to 10 participants, and the starting dose of Wegovy (0.25mg/week semaglutide injection) is also given to 10 participants, over a four-week duration. The trial is designed to evaluate the safety, tolerability and pharmacokinetic profile in overweight or obese participants who are otherwise healthy. Top-line results from SLIM-1 are expected to be available in November.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.

About Cortigent, Inc.

Cortigent, Inc., a wholly owned subsidiary of Vivani, is developing brain implant devices to help patients recover critical body functions. Its patent-protected precision neurostimulation technology platform leverages neuroscience and proprietary microelectronics to create advanced medical devices. Vivani’s predecessor, Second Sight Medical Products, previously marketed Argus® II, the first and only medical device to obtain FDA approval to treat a rare form of blindness. This innovative device has helped hundreds of profoundly blind patients to achieve meaningful visual perception. Cortigent’s next generation investigational system, the Orion® cortical stimulation system, has been designed to treat blindness caused by common conditions including glaucoma and diabetic retinopathy. Orion has an FDA Breakthrough Device designation, completed a 6-year Early Feasibility Study in 2025 with promising safety and efficacy results and is covered by an extensive intellectual property estate. Cortigent is also applying its core technology to improving recovery of arm and hand motion in patients with paralysis due to stroke. For more information and patient videos, please visit: www.cortigent.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:

Donald Dwyer

Chief Business Officer

info@vivani.com

(415) 506-8462

Investor and Media Relations Contact:

Jami Taylor

Investor and Media Relations Advisor

investors@vivani.com

(415) 506-8462

VIVANI MEDICAL, INC.

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except per share data)

June 30,

December 31,

2026

2025

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

19,894

16,232

R&D tax credit incentive receivable

709

654

Prepaid expenses and other current assets

1,032

1,012

Total current assets

21,635

17,898

Property and equipment, net

2,850

2,879

Operating lease right-of-use assets, net

16,169

17,230

Restricted cash

892

1,338

Deposits and other assets

TOTAL ASSETS

41,639

39,393

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Accounts payable

1,195

1,032

Accrued expenses

1,629

1,736

Litigation accrual

1,675

Accrued compensation expense

317

365

Lease liability, current portion

1,843

1,794

Total current liabilities

6,659

6,602

Lease liability, noncurrent portion

16,013

17,061

TOTAL LIABILITIES

22,672

23,663

Commitments and contingencies (Note 12)

Stockholders’ equity:

Common stock, par value $0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 0 and 76,428 at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

180,609

164,225

Accumulated other comprehensive income

Accumulated deficit

(161,683)

(148,533)

TOTAL STOCKHOLDERS' EQUITY

18,967

15,730

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

41,639

39,393

VIVANI MEDICAL, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(In thousands, except per share data)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Operating expenses:

Research and development, net of grants

4,456

4,759

8,957

8,976

General and administrative, net of grants

2,418

2,703

4,864

5,044

Total operating expenses

6,874

7,462

13,821

14,020

Loss from operations

(6,874)

(7,462)

(13,821)

(14,020)

Other income, net

504

318

671

574

Net loss

(6,370)

(7,144)

(13,150)

(13,446)

Net loss per common share - basic and diluted

(0.07)

(0.12)

(0.16)

(0.23)

Weighted average common shares outstanding - basic and diluted

87,090

59,244

84,196

59,240

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: ex992_2.htm · Sequence: 8

GRAPHIC

Filename: c58226787c358962998b.jpg · Sequence: 9

Binary file (9537 bytes)

Download c58226787c358962998b.jpg

GRAPHIC

Filename: c00b47d69f7899bdc6cd.jpg · Sequence: 10

Binary file (255257 bytes)

Download c00b47d69f7899bdc6cd.jpg

GRAPHIC

Filename: c058689b744bff831336.jpg · Sequence: 11

Binary file (325634 bytes)

Download c058689b744bff831336.jpg

GRAPHIC

Filename: c0daa804ee3ab3ce286e.jpg · Sequence: 12

Binary file (216350 bytes)

Download c0daa804ee3ab3ce286e.jpg

GRAPHIC

Filename: c0ea1236879c02986db0.jpg · Sequence: 13

Binary file (358374 bytes)

Download c0ea1236879c02986db0.jpg

GRAPHIC

Filename: c2bacfce5a1fc6631160.jpg · Sequence: 14

Binary file (398929 bytes)

Download c2bacfce5a1fc6631160.jpg

GRAPHIC

Filename: c2cc11d818ac7c73e556.jpg · Sequence: 15

Binary file (313129 bytes)

Download c2cc11d818ac7c73e556.jpg

GRAPHIC

Filename: c322c3e2ca6be4462801.jpg · Sequence: 16

Binary file (301086 bytes)

Download c322c3e2ca6be4462801.jpg

GRAPHIC

Filename: c35284f84549fb617044.jpg · Sequence: 17

Binary file (242828 bytes)

Download c35284f84549fb617044.jpg

GRAPHIC

Filename: c3afdc1f3293f6ef3869.jpg · Sequence: 18

Binary file (652040 bytes)

Download c3afdc1f3293f6ef3869.jpg

GRAPHIC

Filename: c3f0a831d3bfb96e1672.jpg · Sequence: 19

Binary file (329691 bytes)

Download c3f0a831d3bfb96e1672.jpg

GRAPHIC

Filename: c46104a4dd2e05b801c2.jpg · Sequence: 20

Binary file (289711 bytes)

Download c46104a4dd2e05b801c2.jpg

GRAPHIC

Filename: c5ba78f1a1c037430954.jpg · Sequence: 21

Binary file (183263 bytes)

Download c5ba78f1a1c037430954.jpg

GRAPHIC

Filename: c5c84745a5a6c3a581fe.jpg · Sequence: 22

Binary file (412050 bytes)

Download c5c84745a5a6c3a581fe.jpg

GRAPHIC

Filename: c73e7a41737f01dd32fb.jpg · Sequence: 23

Binary file (300294 bytes)

Download c73e7a41737f01dd32fb.jpg

GRAPHIC

Filename: c8c360b9a488cb7d461e.jpg · Sequence: 24

Binary file (317206 bytes)

Download c8c360b9a488cb7d461e.jpg

GRAPHIC

Filename: c92a6992ae5b36a6f53c.jpg · Sequence: 25

Binary file (283870 bytes)

Download c92a6992ae5b36a6f53c.jpg

GRAPHIC

Filename: c96a813c046e1038d184.jpg · Sequence: 26

Binary file (168672 bytes)

Download c96a813c046e1038d184.jpg

GRAPHIC

Filename: c9fad373b5b2c1237908.jpg · Sequence: 27

Binary file (215410 bytes)

Download c9fad373b5b2c1237908.jpg

GRAPHIC

Filename: ca29c376ff5dd7b81ee4.jpg · Sequence: 28

Binary file (180873 bytes)

Download ca29c376ff5dd7b81ee4.jpg

GRAPHIC

Filename: cb4d791da4caf7a769c3.jpg · Sequence: 29

Binary file (247406 bytes)

Download cb4d791da4caf7a769c3.jpg

GRAPHIC

Filename: cc19df2b4bd7d8be9d8f.jpg · Sequence: 30

Binary file (235857 bytes)

Download cc19df2b4bd7d8be9d8f.jpg

GRAPHIC

Filename: cc5bd2d34a29c3bcf6ed.jpg · Sequence: 31

Binary file (444087 bytes)

Download cc5bd2d34a29c3bcf6ed.jpg

GRAPHIC

Filename: cc7ca4cd63c5bb898143.jpg · Sequence: 32

Binary file (253637 bytes)

Download cc7ca4cd63c5bb898143.jpg

GRAPHIC

Filename: ccd8ba484161695f463a.jpg · Sequence: 33

Binary file (214408 bytes)

Download ccd8ba484161695f463a.jpg

GRAPHIC

Filename: cdf4ab4bf811d5a9e134.jpg · Sequence: 34

Binary file (332859 bytes)

Download cdf4ab4bf811d5a9e134.jpg

GRAPHIC

Filename: cdfe3f12a008796488ef.jpg · Sequence: 35

Binary file (357013 bytes)

Download cdfe3f12a008796488ef.jpg

GRAPHIC

Filename: ce8a8c0df93dc5d40fdb.jpg · Sequence: 36

Binary file (184792 bytes)

Download ce8a8c0df93dc5d40fdb.jpg

GRAPHIC

Filename: cf653aa88cccf445f363.jpg · Sequence: 37

Binary file (259790 bytes)

Download cf653aa88cccf445f363.jpg

GRAPHIC

Filename: cfd8c142b5ceb10e6134.jpg · Sequence: 38

Binary file (139089 bytes)

Download cfd8c142b5ceb10e6134.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 40

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-36747

Entity Registrant Name

Vivani Medical, Inc.

Entity Central Index Key

0001266806

Entity Tax Identification Number

02-0692322

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1350 S. Loop Road

Entity Address, City or Town

Alameda

Entity Address, State or Province

Entity Address, Postal Zip Code

94502

City Area Code

415

Local Phone Number

506-8462

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

VANI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration